文献速递神经肿瘤

PET成像在IDH突变型胶质瘤患者中的临床应用与前景

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.
PubMed 文献 · J Neurooncol · 2022-12-29

本综述概述了IDH突变型胶质瘤患者的PET研究,重点讨论氨基酸PET在MRI无对比增强肿瘤中的鉴别诊断、活检靶点定义、治疗计划勾画、治疗相关变化与肿瘤进展区分及烷化剂疗效评估中的作用,并展望靶向IDH突变的PET探针在疗效评估中的潜在价值。

要点

  • IDH突变型胶质瘤常无MRI对比增强,尤其WHO分类2级肿瘤。
  • 氨基酸PET有助于鉴别诊断、活检靶点定义和治疗计划勾画。
  • 靶向IDH突变的PET探针可能有助于IDH抑制剂疗效评估。

核心结论

  • 氨基酸PET在IDH突变型胶质瘤的鉴别诊断、活检靶点定义、治疗计划勾画、治疗相关变化与肿瘤进展区分及烷化剂疗效评估中具有价值。
  • 靶向IDH突变的PET探针可能有助于IDH抑制剂治疗患者的疗效评估。

研究设计与样本

  • 本综述综合概述了IDH突变型胶质瘤患者的PET研究。

主要发现

  • 相当一部分IDH突变型胶质瘤在MRI上无对比增强,尤其WHO中枢神经系统肿瘤分类2级肿瘤。
  • 此类肿瘤的主要诊断挑战包括鉴别诊断、诊断性活检的靶点定义、治疗计划中胶质瘤范围的勾画、治疗相关变化与肿瘤进展的区分及烷化剂疗效评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wollring MM, Werner JM, Ceccon G, et al. Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas. J Neurooncol. 2022. PMID: 36577872. doi:10.1007/s11060-022-04218-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。